N-terminal bromodomain of BRD4 in complex with OTX-015

Experimental Data Snapshot

  • Resolution: 1.19 Å
  • R-Value Free: 0.146 
  • R-Value Work: 0.130 
  • R-Value Observed: 0.130 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Ozer, H.G.El-Gamal, D.Powell, B.Hing, Z.A.Blachly, J.S.Harrington, B.Mitchell, S.Grieselhuber, N.R.Williams, K.Lai, T.H.Alinari, L.Baiocchi, R.A.Brinton, L.Baskin, E.Cannon, M.Beaver, L.Goettl, V.M.Lucas, D.M.Woyach, J.A.Sampath, D.Lehman, A.M.Yu, L.Zhang, J.Ma, Y.Zhang, Y.Spevak, W.Shi, S.Severson, P.Shellooe, R.Carias, H.Tsang, G.Dong, K.Ewing, T.Marimuthu, A.Tantoy, C.Walters, J.Sanftner, L.Rezaei, H.Nespi, M.Matusow, B.Habets, G.Ibrahim, P.Zhang, C.Mathe, E.A.Bollag, G.Byrd, J.C.Lapalombella, R.

(2018) Cancer Discov 8: 458-477

  • DOI: https://doi.org/10.1158/2159-8290.CD-17-0902
  • Primary Citation of Related Structures:  
    5WMA, 5WMD, 5WMG

  • PubMed Abstract: 

    Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is overexpressed in CLL and is enriched proximal to genes upregulated or de novo expressed in CLL with known functions in disease pathogenesis and progression. These genes, including key members of the B-cell receptor (BCR) signaling pathway, provide a rationale for this therapeutic approach to identify new targets in alternative types of cancer. Additionally, we describe PLX51107, a structurally distinct BET inhibitor with novel in vitro and in vivo pharmacologic properties that emulates or exceeds the efficacy of BCR signaling agents in preclinical models of CLL. Herein, the discovery of the involvement of BRD4 in the core CLL transcriptional program provides a compelling rationale for clinical investigation of PLX51107 as epigenetic therapy in CLL and application of BRD4 profiling in other cancers. Significance: To date, functional studies of BRD4 in CLL are lacking. Through integrated genomic, functional, and pharmacologic analyses, we uncover the existence of BRD4-regulated core CLL transcriptional programs and present preclinical proof-of-concept studies validating BET inhibition as an epigenetic approach to target BCR signaling in CLL. Cancer Discov; 8(4); 458-77. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 371 .

  • Organizational Affiliation

    Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Bromodomain-containing protein 4127Homo sapiensMutation(s): 1 
Gene Names: BRD4HUNK1
UniProt & NIH Common Fund Data Resources
Find proteins for O60885 (Homo sapiens)
Explore O60885 
Go to UniProtKB:  O60885
PHAROS:  O60885
GTEx:  ENSG00000141867 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO60885
Sequence Annotations
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
6JF BindingDB:  5WMG IC50: 1000 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.19 Å
  • R-Value Free: 0.146 
  • R-Value Work: 0.130 
  • R-Value Observed: 0.130 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 38.825α = 90
b = 42.217β = 90
c = 92.44γ = 90
Software Package:
Software NamePurpose
HKL-2000data reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

  • Released Date: 2018-08-01 
  • Deposition Author(s): Zhang, Y.

Revision History  (Full details and data files)

  • Version 1.0: 2018-08-01
    Type: Initial release
  • Version 1.1: 2019-02-13
    Changes: Data collection, Database references
  • Version 1.2: 2023-10-04
    Changes: Data collection, Database references, Refinement description